Depo-Provera works by delivering medroxyprogesterone acetate, a synthetic form of progesterone, through quarterly injections. This contraceptive prevents pregnancy primarily by suppressing ovulation, while also creating changes in the uterine lining and cervical mucus that prevent conception. For many Tennessee women with busy lives, the appeal of receiving just four shots per year made this an attractive option compared to remembering daily pills or using other more frequent contraceptive methods.
The potential danger lies in how these synthetic hormones interact with brain tissue. Medical research has established that many meningiomas contain progesterone receptors, essentially creating a biological pathway for hormone-stimulated growth. When the high concentrations of synthetic progestins from Depo-Provera bind to these receptors, they can potentially trigger or accelerate tumor development in susceptible individuals.
A groundbreaking 2021 study published in the BMJ found that women using high-dose progestins had up to 20 times greater risk of developing meningiomas compared to the general population. Even more telling, researchers observed that when patients with existing meningiomas discontinued progestin use, many tumors stopped growing or even decreased in size. This provides compelling evidence of the causal relationship. Despite this mounting scientific evidence, Tennessee women prescribed Depo-Provera were typically not informed about this serious risk when making their contraceptive decisions.